Vijay Karwal
Financieel Directeur/CFO bij Affamed Therapeutics (Us), Inc.
Oorsprong van het eerstegraads netwerk van Vijay Karwal
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Affamed Therapeutics (Us), Inc.
Affamed Therapeutics (Us), Inc. Pharmaceuticals: MajorHealth Technology Part of AffaMed Therapeutics, Affamed Therapeutics (US), Inc. is a clinical stage biopharmaceutical company based in New York, NY. The company focuses on developing and commercializing pharmaceutical, digital, and surgical products to address critical unmet medical needs in ophthalmological, neurological, and psychiatric disorders for patients worldwide. The CEO of the company is Dayao Zhao.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Vijay Karwal via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AffaMed Therapeutics
AffaMed Therapeutics Pharmaceuticals: MajorHealth Technology AffaMed Therapeutics is a Chinese company focused on providing innovative treatments to patients. The company is based in Shanghai, CN. The company's mission and vision are centered around improving patient access to these treatments. The company has a pipeline of products in development to achieve this goal. and has subsidiaries in United States and Hong Kong. The CEO of the company is Dayao Zhao. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
CHINA NEPSTAR CHAIN DRUGSTORE LTD.(ADR) | Drugstore Chains | Investor Relations Contact | |
Everest Medicines (Singapore) Pte Ltd. | Director/Board Member | ||
Harvard Medical School | College/University | Doctorate Degree | |
C-Bridge Capital GP IV Ltd.
C-Bridge Capital GP IV Ltd. Financial ConglomeratesFinance Part of CBC Group Investment Management Ltd., C-Bridge Capital GP IV Ltd. provides investment services. | Financial Conglomerates | Director/Board Member | |
HUGEL, INC. | Biotechnology | Director/Board Member | |
Everest Medicines II BVI Ltd. | Director/Board Member | ||
Everest Medicines II HK Ltd. | Director/Board Member | ||
Everonc Medicines, Inc. | Director/Board Member | ||
Everonc Medicines Ltd. | Director/Board Member | ||
Everest Medicines II Ltd.
Everest Medicines II Ltd. Pharmaceuticals: MajorHealth Technology Everest Medicines II Ltd. develops and commercializes pharmaceutical products. The private company is based in Road Town, Cayman Islands. | Pharmaceuticals: Major | Director/Board Member | |
CBC Group Co., Ltd. | Chief Executive Officer | ||
CBC Group (Singapore) Pte. Ltd.
CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd. | Investment Managers | Chief Executive Officer | |
EVEREST MEDICINES LIMITED | Pharmaceuticals: Major | Chairman | |
FAR EAST HORIZON LIMITED | Finance/Rental/Leasing | Corporate Officer/Principal | |
Standard Chartered Business Consulting Beijing Co. Ltd. | Corporate Officer/Principal | ||
Themes Investment Management Ltd.
Themes Investment Management Ltd. Investment ManagersFinance Themes Investment Management Ltd is a private equity firm founded in 2009. The firm is headquartered in Hong Kong. | Investment Managers | Corporate Officer/Principal | |
C-Bridge Capital Investment Management Ltd. | Chief Executive Officer | ||
I-MAB | Pharmaceuticals: Major | Director/Board Member | |
ASCLETIS PHARMA INC. | Biotechnology | Director/Board Member | |
Nanyang Technological University | College/University | Undergraduate Degree | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Medical Specialties | Director/Board Member | |
Peking University Health Science Center | College/University | Doctorate Degree |
Statistieken
Internationaal
China | 7 |
Kaaimaneilanden | 6 |
Singapore | 4 |
Verenigde Staten | 4 |
Hongkong | 4 |
Sectoraal
Health Technology | 8 |
Finance | 5 |
Consumer Services | 4 |
Retail Trade | 2 |
Operationeel
Director/Board Member | 16 |
Chief Executive Officer | 5 |
Corporate Officer/Principal | 3 |
Chairman | 2 |
Doctorate Degree | 2 |
Sterkste connecties
Insiders | |
---|---|
Wei Fu | 21 |
Dayao Zhao | 4 |
Lucia Qian | 2 |
Annie Lee | 1 |
- Beurs
- Insiders
- Vijay Karwal
- Bedrijfsconnecties